Pacific Biosciences of California Inc
F:P09
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pacific Biosciences of California Inc
F:P09
|
US |
|
Biprogy Inc
OTC:NTULF
|
JP |
|
Resona Holdings Inc
TSE:8308
|
JP |
|
U
|
UBS Group AG
SWB:0UB
|
CH |
|
A
|
Aegean Airlines SA
ATHEX:AEGN
|
GR |
|
Organizacion Soriana SAB de CV
F:OSOB
|
MX |
|
C
|
CH Robinson Worldwide Inc
SWB:CH1A
|
US |
Pacific Biosciences of California Inc
Pacific Biosciences of California, or PacBio, makes DNA sequencing systems that let researchers read long stretches of genetic code. Its main products are sequencing instruments, the consumable chips and reagents used in those machines, and service and support agreements. The company’s technology is aimed at scientists who need highly detailed views of genomes, not consumer or hospital testing. PacBio sells mainly to academic research labs, biotechnology and pharmaceutical companies, government labs, and some clinical and applied testing groups. These customers use the systems for genome assembly, rare disease research, cancer research, plant and animal genetics, and other work where long DNA reads matter. PacBio makes money by placing instruments and then repeatedly selling the consumables that run on them, along with maintenance and support. What sets PacBio apart is its focus on long-read sequencing. Many sequencing tools read DNA in short pieces, but PacBio’s systems are designed to read longer sections, which helps customers detect structural changes, resolve complex regions of the genome, and build more complete genetic maps. That makes PacBio a specialist supplier in a research market where accuracy, depth, and the ability to see difficult parts of the genome are the main reasons to buy.
Pacific Biosciences of California, or PacBio, makes DNA sequencing systems that let researchers read long stretches of genetic code. Its main products are sequencing instruments, the consumable chips and reagents used in those machines, and service and support agreements. The company’s technology is aimed at scientists who need highly detailed views of genomes, not consumer or hospital testing.
PacBio sells mainly to academic research labs, biotechnology and pharmaceutical companies, government labs, and some clinical and applied testing groups. These customers use the systems for genome assembly, rare disease research, cancer research, plant and animal genetics, and other work where long DNA reads matter. PacBio makes money by placing instruments and then repeatedly selling the consumables that run on them, along with maintenance and support.
What sets PacBio apart is its focus on long-read sequencing. Many sequencing tools read DNA in short pieces, but PacBio’s systems are designed to read longer sections, which helps customers detect structural changes, resolve complex regions of the genome, and build more complete genetic maps. That makes PacBio a specialist supplier in a research market where accuracy, depth, and the ability to see difficult parts of the genome are the main reasons to buy.
Revenue: PacBio reported first-quarter revenue of $37.2 million, roughly flat year over year, as record consumable revenue helped offset weaker instrument sales.
Guidance cut: Management lowered the high end of 2026 revenue guidance by $5 million, to a range of $165 million to $175 million, while still expecting consumables to drive growth.
Consumables strength: Consumable revenue hit a third straight record quarter at $21.8 million, with clinical shipments up more than 100% year over year.
Instrument pressure: Revio remained constrained by funding conditions in the Americas, and Vega was softer than expected because of academic funding pressure and a one-time promotion.
Margin outlook: Gross margin fell to 37% due to memory and compute cost pressure, the Vega promotion, and one-time inventory and warranty items, but management expects improvement in Q2.
Strategic progress: PacBio completed the sale of its short-read assets to Illumina, resolved litigation with Personal Genomics of Taiwan, and announced a major AI-related collaboration with Basecamp Research.
Clinical momentum: Management said clinical adoption is becoming the main long-term growth driver, especially in rare disease, carrier screening, and newborn screening.
